Business Context and Reporting Period
Company: Liminatus Pharma, Inc. (LIMN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2026
Reporting Period: Event date February 6, 2026; Signed February 9, 2026
Context: The Company, an emerging growth company, entered into a material definitive agreement to resolve pending litigation and restructure warrant obligations.
Key Financial Metrics
This filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The filing focuses on a specific transaction involving equity and debt resolution.
- Equity Issuance: 4,000,000 shares of Common Stock issued.
- Warrant Surrender: 805,377 warrants surrendered and cancelled.
- Liability Resolution: Settlement of a default judgment totaling approximately $8,015,000 ($7,500,000 principal + ~$515,000 interest).
Material Changes Versus Prior Period
The filing details a material change in the Company's capital structure and legal liabilities:
- Capital Structure: Increase in outstanding common shares by 4,000,000; decrease in outstanding warrants by 805,377.
- Legal Liabilities: Elimination of a $7,500,000 default judgment entered on September 11, 2025, and registered on October 22, 2025, in the Central District of California.
- Legal Status: Dismissal of two pending actions: one in the U.S. District Court for the Central District of California and one in the U.S. District Court for the Southern District of New York.
Guidance, Outlook, and Risks
Management Commentary: The Company resolved the dispute with Clear Street LLC (the "Holder") through a settlement and release agreement. No commission or remuneration was paid in connection with the exchange.
Risks and Contingencies:
- Dilution Risk: The issuance of 4,000,000 shares may dilute existing shareholders.
- Regulatory Compliance: The issuance was unregistered, relying on the exemption under Section 3(a)(9) of the Securities Act of 1933.
- Legal Resolution: While the judgment is settled, the filing notes the prior existence of a default judgment, indicating significant prior legal exposure.
Outlook: The filing does not provide forward-looking financial guidance or operational outlook beyond the resolution of the specific legal matter.
Investor Verification Checklist
- Verify the exact dilution impact of the 4,000,000 new shares on the current share count.
- Confirm the full terms of the Settlement Agreement with Clear Street LLC to ensure no hidden liabilities remain.
- Review the Company's cash position to assess if the warrant settlement was the only method to resolve the $7.5M judgment.
- Check subsequent filings for any impact on the Company's compliance with Nasdaq listing standards regarding share count or equity distribution.